The National Institutes of Health said the U.S. Food and Drug Administration on Tuesday approved cyclodextrin, a drug also known as Adrabetadex, as a treatment for infants with Niemann-Pick Type C disease.

NIH said cyclodextrin extended survival for participants with Niemann-Pick Type C (NPC) in a large, international clinical trial. John Gaitanis, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development, said it is the first FDA-approved treatment for infants with NPC. The announcement did not state how many patients are eligible.

According to NIH, NPC is a rare pediatric neurodegenerative disorder. Mutations in the NPC1 gene reduce a protein needed to move lipids and cholesterol within cells, causing buildup and progressive neurological decline that can lead to early death. NIH said half of cases are identified before age 10, and those detected before age 2 have the worst outcomes. Children may have early delays in reaching milestones and later develop cognitive decline similar to dementia.

NIH said the effort began with a natural history study in 2006 under its Bench-to-Bedside program, followed by an early-phase clinical trial at the NIH Clinical Center after an Investigational New Drug authorization. In 2016, a cooperative research and development agreement supported multisite, multinational late-phase trials. NIH said those trials showed positive biomarker results but did not meet clinical outcome measures needed for approval at the time.

Subsequent analysis of survival data focused on infantile-onset disease, conducted with Beren Therapeutics and Dr. Elizabeth Berry-Kravis at Rush University Medical Center in Chicago, showed increased survival, according to NIH. NIH said data from its natural history and therapeutic studies were critical for the analysis that led to FDA approval.

“For a disease as complex and devastating as Niemann-Pick Type C, there was no shortcut,” NIH Director Jay Bhattacharya, M.D., Ph.D., said. Forbes D. Porter, M.D., Ph.D., of NICHD said the approval is what the team had worked toward since 2006 and follows research that first mapped the gene’s location in 1997.